Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company developing allogeneic CAR T (AlloCAR T) therapies for cancer and autoimmune disease. The ALLO news feed on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how its AlloCAR T pipeline progresses through development.
News about Allogene frequently highlights key milestones in its major programs. For oncology, updates include progress in the pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma, including trial design changes, site activations, and planned interim analyses focused on minimal residual disease (MRD) conversion. For autoimmune disease, releases cover the Phase 1 RESOLUTION trial of ALLO-329, a dual CD19/CD70 AlloCAR T candidate that incorporates the company’s Dagger® technology and is being studied across multiple rheumatologic indications.
Investors and observers can also find news on ALLO-316 in renal cell carcinoma through the TRAVERSE trial, including early clinical response data and discussions with regulators about potential pivotal development. Additional items include quarterly financial results, cash runway commentary, participation in investor and medical conferences, and 8-K summaries of material events such as changes in lymphodepletion strategy or intellectual property developments involving licensed TALEN-based gene-editing technology.
By following ALLO news, readers can track clinical catalysts, safety and biomarker findings, regulatory interactions, and corporate updates that may influence perceptions of Allogene’s AlloCAR T platform and its potential applications in hematologic malignancies, solid tumors, and autoimmune diseases.
Allogene Therapeutics (Nasdaq: ALLO) will host a Research & Development Showcase on November 29, 2022, to discuss its CD19 and BCMA programs. The hybrid event will occur at 10:00 AM PT in New York, with limited in-person attendance. Registration is required. Additionally, Allogene will participate in five investor conferences starting with the Cowen 6th Annual IO Next Summit on November 11, 2022. Webcasts will be available on the company’s website for those unable to attend.
Allogene Therapeutics announced promising results from its Phase 1 UNIVERSAL trial of ALLO-715, an allogeneic CAR T product for multiple myeloma, demonstrating significant responses. The updated data, including safety and efficacy results from lymphodepletion, will be presented at the American Society of Hematology meeting from December 10-13, 2022. The company will also host a Research & Development Showcase on November 29, 2022, to discuss further plans and insights regarding ALLO-715.
Allogene Therapeutics (Nasdaq: ALLO) has initiated the ALPHA2 trial, the first allogeneic CAR T Phase 2 trial aimed at treating relapsed/refractory large B-cell lymphoma. This single-dose trial employs 120 million CAR+ cells alongside a lymphodepletion regimen. The company also is preparing for the EXPAND trial, testing the role of ALLO-647 in lymphodepletion. As of Q3 2022, Allogene reported $637 million in cash and a net loss of $83.1 million. Future developments include an R&D showcase on November 29, 2022, to update clinical data from existing programs.
Allogene Overland Biopharm has completed a cutting-edge AlloCAR T manufacturing facility in Shanghai, enabling production for Greater China, Taiwan, South Korea, and Singapore. This milestone supports the accelerated development of AlloCAR T products, addressing the significant need for cell therapies in Asia. The 68,000 square foot GMP facility is designed for scalable and simultaneous production of multiple therapies. The venture aims to enhance access to allogeneic CAR T options and initiate clinical trials for new indications, marking a pivotal step in cancer treatment in the region.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) will report its third quarter 2022 financial results on November 2, 2022, after the market closes. A live audio webcast and conference call will follow at 2:00 PM PT/5:00 PM ET. Investors can access the live event on the company's website, with a replay available for 30 days. Allogene Therapeutics is dedicated to developing allogeneic CAR T cell products for cancer treatments, aiming to provide accessible cell therapy solutions on-demand.
Allogene Therapeutics (ALLO) has launched the CAR T Together initiative to enhance access to allogeneic CAR T therapies for cancer patients. A recent survey showed that only 50% of eligible patients receive current autologous CAR T treatments, with significant delays in access, as 40% wait three to six months. The initiative aims to accelerate clinical trials for 'off-the-shelf' CAR T products, addressing the challenges of patient demand and manufacturing capacity.
Allogene Therapeutics has initiated the Phase 2 ALPHA2 trial for ALLO-501A in relapsed/refractory large B-cell lymphoma patients, aiming to demonstrate the efficacy of a single-dose regimen paired with ALLO-647. Supported by promising Phase 1 data, the trial will enroll around 100 patients, focusing on the objective response rate as its primary endpoint. The company also plans to launch the EXPAND trial to assess the contribution of ALLO-647. The FDA recently granted Regenerative Medicine Advanced Therapy designation to ALLO-501A, underscoring its potential in addressing unmet treatment needs.
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a biotechnology company focused on allogeneic CAR T (AlloCAR T™) products for cancer, announced its participation in the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, at 6:30 AM Pacific Time. Management will present insights about its pipeline of 'off-the-shelf' CAR T cell candidates aimed at improving availability and scalability of cell therapy. A live webcast will be available on the company’s website, with a replay accessible for 30 days afterwards.
Allogene Therapeutics (ALLO) announced significant developments in its clinical initiatives, including anticipated U.S. FDA clearance for the Phase 2 pivotal trial of ALLO-501A targeting relapsed/refractory large B cell lymphoma (LBCL). This trial could be a first for allogeneic CAR T therapies. The company’s manufacturing facility, Cell Forge 1, is expected to produce approximately 20,000 doses annually. As of June 30, 2022, Allogene reported $686 million in cash and a net loss of $74.8 million for Q2 2022, with increased spending expected in the second half of the year.
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company, announced its participation in three upcoming investor conferences. These include the 42nd Annual Canaccord Genuity Growth Conference on August 11, 2022, the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, and the Baird 2022 Global Healthcare Conference on September 13, 2022. Allogene is focused on developing allogeneic CAR T products for cancer treatment. Webcasts of the presentations will be available on the company’s website.